Predominance of high-grade pathway in breast cancer development of Middle East women

Al‐Kuraya, Khawla S.; Schraml, Peter; Sheikh, Salwa S.; Amr, Samir S.; Torhorst, J.; Tapia, Coya; Novotny, Hedvika; Spichtin, Hanspeter; Maurer, Robert; Mirlacher, Martina; Simon, Ronald; Sauter, Guido

doi:10.1038/modpathol.3800408

Cited by 64 publications

(55 citation statements)

References 20 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While almost of females were positive to ER and PR during the completely reviewed period. The frequency of HER" and MYC was greater in Saudi than Swiss BC cases and they interpreted that due to genetic difference, different lifestyle and to increased incidence of BC cases diagnosed with higher grade [44,45]. Although different study reported that of all tested specimens, 28.3% were positive HER-2/neu which was matching with literature.…”

Section: Discussionsupporting

confidence: 71%

Retrospective Study Assessing Breast Cancer Occurrence and its Risk Factors among Females at Al Ahsa

Hassanein¹,

Hassan²,

Mustafa³

et al. 2017

J Comm Pub Health Nurs

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

Retrospective Study Assessing Breast Cancer Occurrence and its Risk Factors among Females at Al Ahsa

Hassanein¹,

Hassan²,

Mustafa³

et al. 2017

J Comm Pub Health Nurs

View full text Add to dashboard Cite

“…Patients from Asian descent are more likely to have non-small cell lung cancer with epidermal growth factor receptor-activating mutations than patients from the US (18). Moreover, HER2 amplification is more frequent in breast cancers of Korean and Saudi Arabian patients than in those of Caucasian patients (19,20).…”

Section: Resultsmentioning

confidence: 91%

Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients

Köllermann

Albrecht²,

Schlomm³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. Activating mutations in the cytosolic serine/ threonine kinase, BRAF, have been reported in a variety of neoplasms. BRAF activation may contribute to tumor growth via activation of the MAP/ERK kinase pathway, and BRAF represents a possible therapeutic target. Activating BRAF mutations were recently reported in approximately 10% of prostate cancer cases in Asian patients. In the present study, 43 hormone refractory prostate cancers were analyzed for BRAF mutations in order to determine whether anti-BRAF therapy is a suitable approach for advanced prostate cancer patients. In all of the studied tumors, BRAF exons 11 and 15 were PCR-amplified and sequenced, including the backward and forward sequences. BRAF mutations were noted only in the positive control tissues, but were not found in any of the 43 analyzed prostate cancers. We conclude that BRAF mutations occur only rarely in prostate cancers in Caucasian patients and are not associated with tumor progression. The application of anti-BRAF therapies may therefore not be beneficial for prostate cancer.

show abstract

“…A high proportion of BC showing aggressive patterns including high-grade, triple-negative or Her2-positive tumors was reported in BC patients from Saudi Arabia. Saudi women had almost 14-folder lower risk of developing low-grade BC than did Swiss patients, suggesting a high-grade pathway in BC development in Saudi women (Al-Kuraya et al, 2005). The difference in tumor biology between BA patients in southern Israel and patients from Saudi Arabia emphasizes the importance of different acquired factors in the development of BC between these two populations.…”

Section: Discussionmentioning

confidence: 97%

Breast Cancer in Bedouin-Arab Patients in Southern Israel: Epidemiologic and Biologic Features in Comparison with Jewish Patients

Lazarev

Flaschner²,

Geffen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent cancer type and the leading cause of death among women in Israel (BaronApel, Israel Center for Disease Control) a. Time-trends in the incidence of BC have been different in Jewish and Israeli-Arab populations. Following a steady rise over a few decades, the incidence of BC in Jews decreased by 3% from 1996 through 2007. In contrast, the incidence of BC in Israeli-Arabs continued to increase by 98% over the same time-period. Age-adjusted incidence rates in Jews and Israeli-Arabs in 2010 reached levels of 91, and of 53 cases per 100,000 per year, respectively (Israel Cancer Registry, Jerusalem).Bedouin-Arabs (BA), who are part of the Israeli-Arab population of Israel, reside in the Negev, a desert and

show abstract

Predominance of high-grade pathway in breast cancer development of Middle East women

Cited by 64 publications

References 20 publications

Retrospective Study Assessing Breast Cancer Occurrence and its Risk Factors among Females at Al Ahsa

Retrospective Study Assessing Breast Cancer Occurrence and its Risk Factors among Females at Al Ahsa

Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients

Breast Cancer in Bedouin-Arab Patients in Southern Israel: Epidemiologic and Biologic Features in Comparison with Jewish Patients

Contact Info

Product

Resources

About